Spontaneous Intracerebral Hemorrhage and Delayed Cerebral Vasospasm in a Patient with COVID-19 Infection

AUTHORS

Björn Sommer 1 , * , Christoph Maurer 2 , Ansgar Berlis 2 , Ehab Shiban 1

1 Department of Neurosurgery, University Hospital Augsburg, Augsburg, Germany

2 Department of Neuroradiology, University Hospital Augsburg, Augsburg, Germany

How to Cite: Sommer B, Maurer C, Berlis A, Shiban E. Spontaneous Intracerebral Hemorrhage and Delayed Cerebral Vasospasm in a Patient with COVID-19 Infection. Arch Neurosci. 2021;8(3):e116184. doi: 10.5812/ans.116184.

ARTICLE INFORMATION

Archives of Neuroscience: 8 (3); e116184
Published Online: August 21, 2021
Article Type: Case Report
Received: May 17, 2021
Revised: August 6, 2021
Accepted: August 9, 2021
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Introduction: The SARS-CoV-2 may cause vasculitis and thromboembolic events. We report on an unusual case of spontaneous intracerebral hemorrhage and delayed cerebral vasospasms in a patient with COVID-19.

Case Presentation: A 65-year-old male was transferred to the emergency department due to a short period of unconsciousness. Twenty-two hours prior to presentation, the patient had a 39.5°C fever with breathing difficulties. Initial COVID-19 PCR was positive. While conscious and without any neurological impairment, a large right frontal intracerebral hemorrhage (ICH) was detected. A preoperative angiogram showed no pathological blood vessels or vasospasm. The patients had a generalized tonic-clonic seizure due to ICH progression, which led to an immediate microsurgical ICH removal. Thirteen days thereafter, the patient became unconscious again. Angiography revealed severe cerebral vasospasm (CV) that required repetitive percutaneous transluminal angioplasty (PTA) and intra-arterial nimodipine treatment.

Conclusions: We present the first case of ICH and delayed vasospasm associated with COVID-19. In these patients, combined maximum surgical and endovascular therapy is needed.

1. Introduction

The global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is omnipresent. The pathological cellular mechanisms that induce a cytokine release “storm” are believed to go through different phases, which lead to dysregulation of the immune system (1). As the angiotensin-converting-enzyme 2 (ACE2) receptor is a co-receptor for virus spike proteins, it might inflict indirect damage of the cerebrovascular endothelium cells due to an interaction of the viral “S” protein and the ACE2 receptor, leading to inflammation and apoptosis (2). Another mechanism of the pathophysiology of ICH in COVID-19 patients could be the direct interaction of the virus with the endothelium causing rupture of capillaries with subsequent intracerebral hemorrhage. The breakdown of the blood-brain barrier is also induced by pro-inflammatory cytokines, alterations in the coagulation cascade, and complement system. The risk of ICH could also be increased by an accumulation of angiotensin II in the local endothelium due to a downregulation of the ACE2 receptor by SARS-CoV-2, which then interacts with the renin-angiotensin-aldosterone system (3, 4). In this report, we present a rare case of ICH with delayed cerebral vasospasm (CV).

2. Case Presentation

A 65-year-old male suddenly became unconscious while drinking alcoholic beverages. He celebrated a birthday with five families the day before, had a 39.5°C fever but did not follow the rules of social distancing. In his past medical history, he had a sick-sinus syndrome requiring a cardiac pacemaker and a 40 pack-year history. On the day of admission, the blood serum alcohol level was 4.3 g/L. He had no fever or neurological deficits, no cough, and only dyspnoea under physical load. Chest X-ray showed a density of the left basolateral lung without inflammatory reactions. SARS-Corona PCR (Cepheid and Hologic) was positive. D-Dimer was elevated with 9,696 ng/mL, inflammatory parameters were as follow: CRP 5.08 mg/dL, IL-6 95.1 pg/mL, and Thrombocyte count was 81/nL. Shortly after admission, he suffered from a generalized tonic-clonic seizure. CT-scan showed a space-occupying right frontal intracerebral hemorrhage (ICH) and concomitant subdural hematoma (Figure 1). CT-angiography (CT-A) and cerebral angiography (DSA) failed to show any vascular abnormalities. A high-resolution CT of the chest showed no features of COVID-19. Cranial CT follow-up revealed a progression of the ICH, which led to an immediate microsurgical evacuation. The postoperative period was unremarkable. Thirteen days following surgery, the patient became unconscious again. CT-A revealed severe cerebral vasospasm of the right MCA, both ACA and basilar artery requiring repetitive PTAs and intra-arterial nimodipine as well as oral nimodipine treatment regimes. After four days, vasospasm eventually resolved. Due to a malresorptive hydrocephalus, a ventriculoperiotoneal shunt was implanted on day 26 after the occurrence of the ICH. Final CT revealed infarction in the right posterior MCA territory (Figure 1). The patient was transferred to a rehabilitation center with a modified Rankin Scale score of 4.

Figure 1. A, initial cCT depicts right frontal ICH with subdural hematoma; B, in the course of hospital stay, cerebral vasospasm occurred on the 13th postoperative day (angiogram p.a.-projection of right ICA injection); C, after four times of PTA and local spasmolysis, vasospams of the ACA and MCA-territories resolved; D, final cCT after vp-shunt implantation revealed partial infarction of the right posterior MCA-territory.

3. Discussion

We report, to our knowledge, the first case of ICH with delayed severe cerebral vasospasms in a COVID-19. Neurovascular injuries after SARS-CoV-2 infection are one of the important manifestations, with a reported stroke incidence of 1 - 2% of all COVID-19 hospitalized patients (5). The relationship between spontaneous intracerebral hemorrhage and the SARS-CoV-2 infection remains unclear. A recent European multicenter study reported on 18 patients with acute intracranial hemorrhage. Although a direct association between the infection could not be proven, they concluded it might be more likely in patients with severe symptoms of COVID-19 (6). This is in line with previous reports that critically ill patients are prone to cerebrovascular complications (7). Our patient, however, had mild respiratory symptoms and was intubated due to his neurological deterioration. It is not clear whether a direct viral infection or an indirect pathomechanism such as an inflammatory reaction, dysfunction of the coagulation pathway, or an autoimmune mechanism causes cerebrovascular damage. There are at least three possible mechanisms responsible for the development of CV in COVID-19 patients. First, the ICH itself can induce CV due to CSF heme products that induce oxidative stress and inflammation (8, 9). Second, vasculitis is seen in cerebral vessels of patients with SARS-CoV-2, which can explain endothelial damage and vasoconstriction leading to CV (10). Third, a reversible vasoconstriction syndrome (RCVS) of cerebral arteries has been described (11, 12). Another patient succumbed to a devastating diffuse arterial and dural venous sinus construction with generalized cerebral edema four days after admission (13). It was hypothesized that SARS-CoV-2 might induce vasoconstriction due to downregulation of the ACE2 receptor, which then provoked an over activation of the renin-angiotensin-aldosterone axis. In non-COVID-19 patients, the RCVS can cause ICH in about 34 - 43% of cases, possibly due to a failure in cerebral autoregulation with reperfusion injury-causing rupture of cortical blood vessels (11, 14). In our patient, we suspect a strong association between the occurrence of the COVID-19, spontaneous ICH, and subsequent CV; however, the hypothesis of a direct interaction of the virus crossing the blood-brain barrier cannot be proven in our patient. The analysis of the CSF revealed no specific SARS-CoV-2-virus RNA in our patient. This finding does not exclude the suggested pathomechanism and is in accordance with other case reports (15).

Footnotes

References

  • 1.

    Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: A review of the phases of illness and therapeutic agents. Virol J. 2020;17(1):154. doi: 10.1186/s12985-020-01415-w. [PubMed: 33059711]. [PubMed Central: PMC7558250].

  • 2.

    Losy J. SARS-CoV-2 infection: Symptoms of the nervous system and implications for therapy in neurological disorders. Neurol Ther. 2021;10(1):31-42. doi: 10.1007/s40120-020-00225-0. [PubMed: 33226565]. [PubMed Central: PMC7681771].

  • 3.

    Eleuteri D, Montini L, Cutuli SL, Rossi C, Alcaro F, Antonelli M. Renin-angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: A preliminary report. Crit Care. 2021;25(1):91. doi: 10.1186/s13054-021-03507-7. [PubMed: 33648544]. [PubMed Central: PMC7919982].

  • 4.

    Abbas R, El Naamani K, Sweid A, Schaefer JW, Bekelis K, Sourour N, et al. Intracranial hemorrhage in COVID-19 patients: A case series. World Neurosurg. 2021. doi: 10.1016/j.wneu.2021.07.067. [PubMed: 34298138]. [PubMed Central: PMC8294594].

  • 5.

    Gutierrez Amezcua JM, Jain R, Kleinman G, Muh CR, Guzzetta M, Folkerth R, et al. COVID-19-induced neurovascular injury: A case series with emphasis on pathophysiological mechanisms. SN Compr Clin Med. 2020;2(11):2109-25. doi: 10.1007/s42399-020-00598-1. [PubMed: 33106782]. [PubMed Central: PMC7577845].

  • 6.

    Nawabi J, Morotti A, Wildgruber M, Boulouis G, Kraehling H, Schlunk F, et al. Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage. J Clin Med. 2020;9(8). doi: 10.3390/jcm9082543. [PubMed: 32781623]. [PubMed Central: PMC7464657].

  • 7.

    Fraiman P, Godeiro Junior C, Moro E, Cavallieri F, Zedde M. COVID-19 and cerebrovascular diseases: A systematic review and perspectives for stroke management. Front Neurol. 2020;11:574694. doi: 10.3389/fneur.2020.574694. [PubMed: 33250845]. [PubMed Central: PMC7674955].

  • 8.

    de Oliveira Manoel AL, Goffi A, Marotta TR, Schweizer TA, Abrahamson S, Macdonald RL. The critical care management of poor-grade subarachnoid haemorrhage. Crit Care. 2016;20:21. doi: 10.1186/s13054-016-1193-9. [PubMed: 26801901]. [PubMed Central: PMC4724088].

  • 9.

    Kiphuth IC, Huttner HB, Breuer L, Engelhorn T, Schwab S, Kohrmann M. Vasospasm in intracerebral hemorrhage with ventricular involvement: A prospective pilot transcranial Doppler sonography study. Cerebrovasc Dis. 2011;32(5):420-5. doi: 10.1159/000330652. [PubMed: 21986490].

  • 10.

    Cezar-Junior AB, Faquini IV, Silva JLJ, de Carvalho Junior EV, Lemos L, Freire Filho JBM, et al. Subarachnoid hemorrhage and COVID-19: Association or coincidence? Medicine (Baltimore). 2020;99(51). e23862. doi: 10.1097/MD.0000000000023862. [PubMed: 33371170]. [PubMed Central: PMC7748374].

  • 11.

    Dakay K, Kaur G, Gulko E, Santarelli J, Bowers C, Mayer SA, et al. Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection. J Stroke Cerebrovasc Dis. 2020;29(9):105011. doi: 10.1016/j.jstrokecerebrovasdis.2020.105011. [PubMed: 32807426]. [PubMed Central: PMC7274589].

  • 12.

    Mansoor T, Alsarah AA, Mousavi H, Khader Eliyas J, Girotra T, Hussein O. COVID-19 associated reversible cerebral vasoconstriction syndrome successfully treated with nimodipine and aspirin. J Stroke Cerebrovasc Dis. 2021;30(7):105822. doi: 10.1016/j.jstrokecerebrovasdis.2021.105822. [PubMed: 33895426]. [PubMed Central: PMC8041144].

  • 13.

    Sirous R, Taghvaei R, Hellinger JC, Krauthamer AV, Mirfendereski S. COVID-19-associated encephalopathy with fulminant cerebral vasoconstriction: CT and MRI findings. Radiol Case Rep. 2020;15(11):2208-12. doi: 10.1016/j.radcr.2020.08.024. [PubMed: 32837672]. [PubMed Central: PMC7428683].

  • 14.

    Patel SD, Topiwala K, Saini V, Patel N, Pervez M, Al-Mufti F, et al. Hemorrhagic reversible cerebral vasoconstriction syndrome: A retrospective observational study. J Neurol. 2021;268(2):632-9. doi: 10.1007/s00415-020-10193-y. [PubMed: 32894331].

  • 15.

    Al Saiegh F, Ghosh R, Leibold A, Avery MB, Schmidt RF, Theofanis T, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. J Neurol Neurosurg Psychiatry. 2020;91(8):846-8. doi: 10.1136/jnnp-2020-323522. [PubMed: 32354770].

  • Copyright © 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
    COMMENTS

    LEAVE A COMMENT HERE: